Rapport Therapeutics, a precision neuromedicines company, welcomes Dr. John Maraganore, a renowned industry leader, to its Board of Directors. With his expertise in RNAi therapeutics and building science-based companies, Dr. Maraganore will guide Rapport in revolutionizing care for patients with neurological disorders.
Introducing Dr. John Maraganore to Rapport Therapeutics' Board of Directors
( Credit to: Citybiz )
Rapport Therapeutics, a precision neuromedicines company, has recently appointed Dr. John Maraganore to its Board of Directors. With his renowned industry leadership and expertise in RNAi therapeutics, Dr. Maraganore brings a wealth of experience to the company.
As the former founding CEO of Alnylam Pharmaceuticals, Dr. Maraganore played a pivotal role in the development of RNAi therapeutics, a novel class of medicines. During his tenure at Alnylam, he oversaw the company's growth, with a market capitalization of over $25 billion. Under his leadership, Alnylam successfully established multiple major pharmaceutical alliances and brought four RNAi medicines to market.
With Dr. Maraganore's guidance, Rapport Therapeutics aims to revolutionize care for patients with neurological disorders. The company is focused on advancing its pipeline of precision neuroscience product candidates to address the significant unmet need in the treatment of neurological disorders. By leveraging its innovative platform, Rapport Therapeutics aims to provide patients with better alternatives to existing treatments for central nervous system disorders.
Precision Neuromedicines: Rapport Therapeutics' Targeted Approach
Rapport Therapeutics has developed and refined a platform over the past decade that utilizes receptor-associated proteins (RAPs) to achieve precision in targeting specific regions or neural circuits in the brain. This targeted approach has the potential to improve tolerability and clinical benefit for patients, addressing the limitations and side effects associated with current treatment options.
The company is currently conducting clinical trials in epilepsy and has ongoing discovery-stage programs in neuropathic pain, hearing disorders, and bipolar disorder. By leveraging its innovative platform, Rapport Therapeutics aims to provide patients with better alternatives to existing treatments for central nervous system disorders.
Dr. John Maraganore: A Valuable Addition to Rapport Therapeutics
Dr. John Maraganore's appointment to the Board of Directors further strengthens Rapport's leadership team. With his wisdom and experience, he will play an instrumental role in guiding the company as it works towards its goal of becoming a preeminent precision neuroscience company.
His impressive track record in building science-based companies, particularly in the field of RNAi therapeutics, makes him an invaluable addition to Rapport Therapeutics. With his guidance, the company aims to revolutionize care in the field of neurological disorders and positively impact the lives of patients with debilitating conditions.
Conclusion: Advancing Precision Neuromedicines with Dr. John Maraganore
The appointment of Dr. John Maraganore to Rapport Therapeutics' Board of Directors marks a significant milestone for the company. With his extensive experience and leadership in the field of biotechnology, Dr. Maraganore will play a vital role in advancing Rapport's pipeline of precision neuromedicines and bringing much-needed treatment options to patients with neurological disorders.
Under Dr. Maraganore's guidance, Rapport Therapeutics aims to revolutionize care for patients with neurological disorders by leveraging its innovative platform and targeted approach. By providing better alternatives to existing treatments, the company strives to improve the lives of those affected by central nervous system disorders.